Marinus Pharmaceuticals (MRNS) Leaps on Study Update

Marinus Pharmaceuticals Inc (NASDAQ: MRNS) shares rose 35.3% to $1.57 following preliminary study update. Marinus Pharmaceuticals reported positive preliminary data from children with CDKL5 genetic disorder. Share volume totaled 21.1 million, overwhelming an all-day average of 924,000